Page 98 - TD-4-3

Tumor Discovery Sorafenib induces MVPs in NSCLC

2017;18(5):1007. 41. Kim YS, Jin HO, Seo SK, et al. Sorafenib induces apoptotic
cell death in human non-small cell lung cancer cells by
doi: 10.3390/ijms18051007
down-regulating mammalian target of rapamycin (mTOR)-
31. Goldkorn T, Chung S, Filosto S. Lung cancer and lung dependent survivin expression. Biochem Pharmacol.
injury: The dual role of ceramide. Handb Exp Pharmacol. 2011;82(3):216-226.
2013;216:93-113.
doi: 10.1016/j.bcp.2011.04.011
doi: 10.1007/978-3-7091-1511-4-5
42. Li Y, Yan H, Xu X, Liu H, Wu C, Zhao L. Erastin/sorafenib
32. Irep N, Inci K, Tokgun PE, Tokgun O. Exosome inhibition induces cisplatin-resistant non-small cell lung cancer cell
improves response to first-line therapy in small cell lung ferroptosis through inhibition of the Nrf2/xCT pathway.
cancer. J Cell Mol Med. 2024;28(4):e18138. Oncol Lett. 2020;19(1):323-333.
doi: 10.1111/jcmm.18138 doi: 10.3892/ol.2019.11066
33. Xiang H, Jin S, Tan F, Xu Y, Lu Y, Wu T. Physiological 43. Lei C, Liu D, Zhou Q, Ma S, Qian H. RETRACTED:
functions and therapeutic applications of neutral Engineering of dopamine conjugated with bovine serum
sphingomyelinase and acid sphingomyelinase. Biomed albumin and zeolite imidazole framework: A promising
Pharmacother. 2021;139:111610. drug delivery nanocarrier on lung cancer cells. Heliyon.
doi: 10.1016/j.biopha.2021.111610 2024;10(17):e36580.
34. Companioni O, Mir C, Garcia-Mayea Y, LLeonart ME. doi: 10.1016/j.heliyon.2024.e36580
Targeting sphingolipids for cancer therapy. Front Oncol. 44. Bow YD, Ko CC, Chang WT, et al. A novel quinoline
2021;11:745092. derivative, DFIQ, sensitizes NSCLC cells to ferroptosis by
doi: 10.3389/fonc.2021.745092 promoting oxidative stress accompanied by autophagic
dysfunction and mitochondrial damage. Cancer Cell Int.
35. Hoshi A, Kanzawa F, Kuretani K. Enhancement of antitumor 2023;23(1):171.
activity of cyclophosphamide with imipramine. Chem
Pharm Bull (Tokyo). 1969;17(8):1694-1697. doi: 10.1186/s12935-023-02984-w
doi: 10.1248/cpb.17.1694 45. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal
growth factor receptor mutations in lung cancer. Nat Rev
36. Wang Y, Wang X, Wang X, et al. Imipramine impedes Cancer. 2007;7(3):169-181.
glioma progression by inhibiting YAP as a hippo pathway
independent manner and synergizes with temozolomide. doi: 10.1038/nrc2088
J Cell Mol Med. 2021;25(19):9350-9363. 46. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits
doi: 10.1111/jcmm.16874 broad spectrum oral antitumor activity and targets the
RAF/MEK/ERK pathway and receptor tyrosine kinases
37. Chryplewicz A, Scotton J, Tichet M, et al. Cancer cell involved in tumor progression and angiogenesis. Cancer
autophagy, reprogrammed macrophages, and remodeled Res. 2004;64(19):7099-7109.
vasculature in glioblastoma triggers tumor immunity.
Cancer Cell. 2022;40(10):1111-1127.e9. doi: 10.1158/0008-5472.Can-04-1443
doi: 10.1016/j.ccell.2022.08.014 47. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in
advanced clear-cell renal-cell carcinoma. N Engl J Med.
38. Li J, Pan YY, Zhang Y. Synergistic interaction between 2007;356(2):125-134.
sorafenib and gemcitabine in EGFR-TKI-sensitive and
EGFR-TKI-resistant human lung cancer cell lines. Oncol doi: 10.1056/NEJMoa060655
Lett. 2013;5(2):440-446. 48. Zingone A, Brown D, Bowman ED, et al. Relationship
doi: 10.3892/ol.2012.1017 between anti-depressant use and lung cancer survival.
Cancer Treat Res Commun. 2017;10:33-39.
39. Martinelli E, Troiani T, Morgillo F, et al. Synergistic antitumor
activity of sorafenib in combination with epidermal growth doi: 10.1016/j.ctarc.2017.01.001
factor receptor inhibitors in colorectal and lung cancer cells. 49. Chen C, Ju R, Shi J, et al. Carboxyamidotriazole synergizes
Clin Cancer Res. 2010;16(20):4990-5001. with sorafenib to combat non-small cell lung cancer through
doi: 10.1158/1078-0432.Ccr-10-0923 inhibition of NANOG and aggravation of apoptosis.
J Pharmacol Exp Ther. 2017;362(2):219-229.
40. Wang J, Ma S, Chen X, Zhang S, Wang Z, Mei Q. The novel
PI3K inhibitor S1 synergizes with sorafenib in non-small doi: 10.1124/jpet.117.240986
cell lung cancer cells involving the Akt-S6 signaling. Invest 50. Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC,
New Drugs. 2019;37(5):828-836.
Hwang JJ. Sorafenib pretreatment enhances radiotherapy
doi: 10.1007/s10637-018-0698-2 through targeting MEK/ERK/NF-κB pathway in human

Volume 4 Issue 3 (2025) 90 doi: 10.36922/TD025110019